EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival

Marcelo C Pasquini iD, Paul K Wallace iD, Brent Logan iD, Manmeet Kaur, Joseph D Tario, Alan Howard, Yali Zhang, Claudio Brunstein, Yvonne Efebera, Nancy Geller iD, Sergio Giralt iD, Parameswaran Hari iD und 11 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.23.00934 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Marcelo C Pasquini und 22 weiteren Autor:innen. Beteiligte Einrichtung: Medical College of Wisconsin, Milwaukee, WI. Hauptthemen laut MEDLINE: Neoplasm, Residual, Lenalidomide, Multiple Myeloma, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Prognostic Immunophenotyping in Myeloma Response (PRIMeR) is an ancillary study of minimal residual disease (MRD) assessment for multiple myeloma by next-generation multiparameter flow cytometry (MFC). Patients were enrolled on a three-arm randomized control trial (Blood and Marrow Transplants Clinical Trials Network 0702 Stem Cell Transplant for Myeloma in Combination of Novel Agents [STaMINA]; ClinicalTrials.gov identifier: NCT01109004 ). METHODS Four hundred and thirty-five patients consented to the MRD panel, which included 10 monoclonal antibodies measured via six-color MFC. MRD was measured at baseline/preautologous hematopoietic cell transplant (BL/preAutoHCT), premaintenance (PM), and 1 year (Y1) after AutoHCT with a sensitivity of 10 –5 to 10 –6 . The primary objective was to assess MRD-negative (MRD neg ) at 1 year after AutoHCT and progression-free survival and overall survival (PFS/OS). RESULTS Similar to the STaMINA results, at a median follow-up of 70 months, there was no significant difference in PFS/OS by treatment arm in the PRIMeR patients. MRD neg at all three time points was associated with significantly improved PFS, and MRD neg at Y1 had significantly longer OS. Multivariate analysis of PFS, adjusting for disease risk and treatment arm, demonstrated hazard ratios (HRs) in MRD-positive patients compared with MRD neg patients at BL, PM, and Y1 of 1.55 ( P = .0074), 1.83 ( P = .0007), and 3.61 ( P < .0001), respectively. Corresponding HRs for OS were 1.19 ( P = .48), 0.88 ( P = .68), and 3.36 ( P < .001). Patients with sustained MRD neg or who converted to MRD neg by Y1 had similar PFS/OS. CONCLUSION To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRD neg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm, ResidualLenalidomideMultiple MyelomaHematopoietic Stem Cell TransplantationTransplantation, AutologousHumansMaleMiddle AgedFemaleAgedAdultMaintenance ChemotherapyFlow CytometryProgression-Free Survival

Substanzen

Lenalidomide

Autor:innen und Institutionen

  • Medical College of Wisconsin, Milwaukee, WI.
  • Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • National Marrow Donor Program, Minneapolis, MN.
  • University of Minnesota, Minneapolis, MN.
  • OhioHealth, Columbus, OH.
  • Ohio State University, Columbus, OH.

ORCID-Profile: Marcelo C Pasquini, Paul K Wallace, Brent Logan, Nancy Geller, Sergio Giralt, Parameswaran Hari, Mary M Horowitz, Amrita Krishnan, Heather Landau, Dan T Vogl, Philip L McCarthy, Theresa Hahn

Förderung

  • NHLBI NIH HHS
  • NCI NIH HHS

Zitieren

APA

Pasquini, M. C., Wallace, P. K., Logan, B., Kaur, M., Tario, J. D., Howard, A., Zhang, Y., Brunstein, C., Efebera, Y., Geller, N., Giralt, S., Hari, P., Horowitz, M. M., Koreth, J., Krishnan, A., Landau, H., Somlo, G., Shah, N., Stadtmauer, E., …, & Hahn, T. (2024). Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.00934

Vancouver

Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, et al. Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.00934

BibTeX
@article{Pasquini2024,
  author = {Pasquini, Marcelo C and Wallace, Paul K and Logan, Brent and Kaur, Manmeet and Tario, Joseph D and Howard, Alan and Zhang, Yali and Brunstein, Claudio and Efebera, Yvonne and Geller, Nancy and Giralt, Sergio and Hari, Parameswaran and Horowitz, Mary M and Koreth, John and Krishnan, Amrita and Landau, Heather and Somlo, George and Shah, Nina and Stadtmauer, Edward and Vogl, Dan T and Vesole, David H and McCarthy, Philip L and Hahn, Theresa},
  title = {Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.23.00934}
}
Kostenlos starten →